Drugs / DTaP-HB-PRP~T vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00534833 | Sep 2007 → Sep 2008 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-HB-PRP~T vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00534833 ↗ |
| Modality | Vaccine | “booster vaccination of DTaP-HB-PRP~T or Tritanrix-HepB/Hib™” NCT00534833 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00534833 ↗ |